Valutazione di efficacia di un antiangiogenetico (Bevacizumab)

[81] Lee CG, Heijn M, Di Tommaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain
RK, et al. Anti-vascular endothelial growth factor treatment augments tumour radiation response under
normoxic or hypoxic conditions. Cance Res 2000; 60: 5565-70
[82] Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular
endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and
improves drug penetration in tumours. Cancer Res 2004; 64:3731-6
[83] Hicklin DJ, Ellis LM, Role of vascular endothelial growth factor pathway in tumor growth and
angiogenesis.J Clin Oncol 2005; 23: 1011-27.
[84] Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann Jd, Vassel A. A
phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.Semin Oncol
2003: 30:117-24
[85] Traina TA, Dickler MN, Caravelli JF, Yeh BM, Brogi E, Panageas K, Flores SA, Norton L, Park J, Hudis
C, Rugo H. A phase II of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with
hormone receptor-positive metastatic breast cancer [abstract 2030].Breast Cancer Res Treat 2005; 94: S 93
[86] Ramaswamy B, Rhoades CA, Kendra K, Hauger M, Allen J, Jhaveri S, Chen H, Cagnoni P, Eckhardt
GS, Elias A, Shapiro CL, CTPE-sponsored phase II trial of bevacizumab (Avastin) in combination with
docetaxel (Taxotere) in metastatic breat cancer [SABCS, oral presentation]. Breast Cancer Res Treat 2003;
82:S50.
[87] Burstein H, Parker L, Savoie J et al. Phase II trial of the anti-VEGF antibody bevacizumab in
combination with vinorelbine for refractory advanced breast cancer [abstract 446].Breast Cancer Res Treat
2002; 76: S115.
[88] Pegram M, Yeon C, Ku NC, Gaudreault J, slamon DJ, Phase I combined biological therapy of breast
cancer using two humanized monoclonal antibodies directed against HER2 protooncogene and vascular
endothelial growth factor (VEGF).San Antonio Breast CancerSymposium (SABCS) Poster presentation 2004
[89] Rugo H, Dickler MN, Scott Jh, More Dh, Melisko M, Keh BM, Caravelli Jf, Brogi E, Hudis C, Park JW.
Change in circulation endothelial cells (CEC) and tumour cells (CTC) in patients (pts) receiving bevacizumab
and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation [abstract 525]. J
Clin Oncol 2005; 23:10s
[90] Presta LG; Chen H, O‟Connor SJ et al: Humanization of an antivasculr endothelial growth factor
monoclonal antibody for the therapy of solid tumors and others disorders: Cance rRes 1997; 57: 4593-9.
[91] NG SS; WD Figg. Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation
vehicles and binding proteins. Cancer Res 2004; 64:821-4.
[92] Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK; Shen J, Sledge GW Jr. The antiangiogenic
property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular
Maria Pittalis
Valutazione di efficacia di un antiangiogenetico (Bevacizumab) associata a chemioterapia in pazienti con carcinoma
della mammella metastatico
Tesi di dottorato in scienze Biomediche-Epidemiologia molecolare dei tumori
Università degli Studi di Sassari
87